Answers are grounded in this paper and cite their sources.
Lipid nanoparticles are the default vehicle for RNA medicines, and the ionizable lipid is the component that makes them work. Its protonatable amine is asked to perform three unrelated tasks: to condense a polyanionic cargo at pH 4, to disrupt the endosomal membrane at pH 5-6, and to remain invisible to innate immunity and to the complement system. All three depend on the same chemical variable - the density, basicity and presentation of the amine - so they cannot be optimized independently, and a decade of medicinal chemistry has consisted largely of trading one against another. Here we argue that this coupling, rather than potency, is the central problem of the field. We examine what the protonation switch does and does not determine, show that tissue address is set by the protein corona rather than by the lipid, and trace how the amine headgroup became the platform’s adjuvant. We then set out a modular design logic in which address, escape and silence are encoded in separate components, and specify the measurements that would show whether such particles actually work.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: